Search Abstracts Program

Session 60   Poster Session Antiretroviral Chemotherapy in Drug Naïve Patients 4:30-6:30 pm 4E-F

Click on the to view the poster for an abstract.

408-W.	A Comparison of AZT/3TC vs 3TC/d4T and ddI/d4T in Combination with Efavirenz as First Line Therapy: Efficacy and Safety Results after 48 Weeks M. R. Domula*1, J. C. Wasmuth1, A. Jütte2, G. Fätkenheuer2, M. Oette3, A. Theisen3, C. Höhn4, H. Knechten4, B. Pfeil5, S. Fenske6, A. Rieke7, and J. K. Rockstroh1 1Univ. of Bonn; 2Univ. of Köln; 3Univ. of Düsseldorf; 4PZB Aachen; 5Univ. of Leipzig; 6Hamburg; and 7Hosp. Kemper Hof, Koblenz, Germany Add to Itinerary
409-W.	Once-Daily vs Twice-Daily Kaletra (Lopinavir/Ritonavir) in Antiretroviral-Naïve HIV+ Patients: 48-Week Follow-Up J. J. Eron*1, B. Bernstein11, M. King11, L. Manning11, R. Bertz11, G. Beall2, F. Carpio-Cedraro3, J. Feinberg4, H. Horowitz5, D. Wheeler6, H. Kessler7, D. Mildvan8, P. Ruane9, B. Yangco10, C. Renz11, S. Mayer11, and E. Sun11 1Univ. North Carolina, Chapel Hill; 2Harbor-Univ. of California, Los Angeles Med. Ctr., 3Alta Med. Hlth. Services, Los Angeles, CA; 4Univ. of Cincinnati, OH; 5Westchester Med. Ctr., Valhalla, NY; 6Annandale, VA; 7Rush Med. Coll., Chicago, IL; 8Beth Israel Med. Ctr., New York, NY; 9Los Angeles, CA; 10Infectious Disease Res. Inst., Tampa, FL; and 11Abbott Labs., Abbott Park, IL Add to Itinerary
410-W.	CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine (NVP) and/or Hydroxyurea (HU) to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects M. Beniowski*, R. Wood, G. Gray, A. Horban, R. Schmidt, A. Lazzarin, A. Lafeuillade, D. Paes, H. Carlier, D. Blanckenberg, E. van Weert, R. van Leeuwen, and J. Lange for the CHARM Trial Study Team Academic Med. Ctr., Univ. of Amsterdam, The Netherlands Add to Itinerary
411-W.	Stavudine XR vs Stavudine IR as Part of Potent Antiretroviral Combination Therapy: 24-Week Safety and Antiviral Efficacy R. Pollard*1, P. Ive2, C. Farthing3, M. Whelden4, S. Thompson4, and H. Brett-Smith4 1Univ. of Texas Med. Branch, Galveston; 2Wits Hlth. Consortium, Parktown, CA; 3AIDS Healthcare Fndn., Los Angeles, CA; and 4Bristol-Myers Squibb, Wallingford, CT Add to Itinerary
412-W.	Antiviral and Immunological Effects of Hydroxyurea (HU) plus HAART vs HAART Alone in Peripheral Blood and Lymphoid Tissue H. J. Stellbrink*1, J. van Lunzen1, N. Frahm1, H. Jessen2, A. Adam3, L. Weitner3, A. Plettenberg4, A. Stoehr4, K. Dalhoff5, B. Kuhlmann6, C. Hoffmann7, H. Horst7, S. Fenske8, K. Tenner-Racz9, and P. Racz9 1Univ. Hosp. Eppendorf, Hamburg; 2Berlin; 3,4,8Hamburg; 5Univ. of Lübeck, 6Hannover; 7Univ. of Kiel; and 9Bernhard-Nocht Inst., Hamburg, Germany Add to Itinerary

---